Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
US Department of Justice
Merck
Accenture
Daiichi Sankyo
Harvard Business School

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 10,238,656

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,238,656
Title:Combination therapy for cancer
Abstract: The present invention provides preparation of medicaments for use in treating and methods of treating non-small cell lung cancer in a patient comprising: [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-i- sopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in combination, as further described herein, with an anti-VEGFR2 antibody, preferably, ramucirumab.
Inventor(s): Chan; Edward Michael (Greenwood, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:15/115,995
Patent Claims:see list of patent claims

Details for Patent 10,238,656

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Eli Lilly And Co CYRAMZA ramucirumab INJECTABLE;INJECTION 125477 001 2014-04-21   Try a Free Trial Eli Lilly and Company (Indianapolis, IN) 2039-04-26 RX search
Eli Lilly And Co CYRAMZA ramucirumab INJECTABLE;INJECTION 125477 002 2014-04-21   Try a Free Trial Eli Lilly and Company (Indianapolis, IN) 2039-04-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Accenture
Fuji
Cipla
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.